Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOST | Q9BQB4 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 2/20 | 0.30 |
| ▸ | MMP10 | P09238 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24972953 | 0.86 | DDB1 (0.33) | DDB1CRBNKMT2AMMP13MMP10 | |
| SCHEMBL24808855 | 0.83 | KMT2A (0.35) | SOSTDDB1CRBNKMT2AMEN1 | |
| SCHEMBL22020905 | 0.82 | — | — | |
| SCHEMBL25753295 | 0.80 | ALDH1A1 (0.36) | SOSTKMT2AMEN1MAPTCYP2C9 | |
| SCHEMBL25753717 | 0.80 | KMT2A (0.34) | KMT2A | |
| SCHEMBL22021450 | 0.79 | CYP2E1 (0.32) | KMT2ACYP2C9 | |
| SCHEMBL12870940 | 0.78 | KMT2A (0.38) | KMT2AMAPTCYP2C9MMP13MMP10 | |
| SCHEMBL25753718 | 0.75 | PGK1 (0.33) | SOSTDDB1CRBN | |
| SCHEMBL12870937 | 0.74 | KMT2A (0.36) | KMT2AMAPTCYP2C9MMP13MMP10 | |
| SCHEMBL17412813 | 0.71 | KMT2A (0.32) | DDB1CRBNKMT2AMAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-08-17 | — | — | US | disclosed |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | SOST 3246/4885DDB1 348/4885CRBN 4767/4885 |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | SOST 3246/4885DDB1 348/4885CRBN 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.